Suggested Searches

photo of Amy M Schell
859-276-0414

Amy M Schell, MD

Hematology Oncology
Gender: Female
4.9 of 5 (220 Ratings)
Accepting New Patients
Virtual Visits

Clinical Focus

Breast Cancer, Cancerous tumors

Practice Locations

A:
Baptist Health Medical Group Hematology & Oncology
1700 Nicholasville Road, Suite 1100
Lexington, KY 40503
859-276-0414 859-276-3765

Education

Fellowship

Dartmouth-Hitchcock Medical Center

Residency

Dartmouth-Hitchcock Medical Center

Medical School

University of Kentucky College of Medicine

Fellowship

Washington University in St. Louis

Board Certifications

-

American Board of Internal Medicine

-

American Board of Internal Medicine

Hospital Affiliations

  • Baptist Health Medical Group
  • Baptist Health Richmond
  • Baptist Health Lexington

Philosophy of Care

Baptist Health Medical Group is a comprehensive, multispecialty network of physicians and advanced practice clinicians. Our providers are committed to providing compassionate, patient-centered care and strive to treat our patients the way we would want to be treated, every time, at every Baptist Health location.

Reviews

Patient Experience Ratings

The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Overall Rating
4.9 out of 5 (220 Ratings)
Review Categories
Patient Comments

Research

  • Breast Cancer (WIRB-22-0127)

    TOL2506A-EXT: Open-label, Safety Extension Study for Subjects with Hormone-Receptor Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA) Study.

    Trial Details
  • Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anat

    A011801: The COMPASSHER2 Trials (Comprehensive Use Of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T=

    Trial Details
  • Breast Cancer

    TOL2506A: A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor Positive

    Trial Details
  • Breast Cancer (WIRB-22-0111)

    Tropion 02: A Phase 3, Open-label, Randomized Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator’s Choice of Chemotherapy in Patients who are not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast02).

    Trial Details
  • ER-Positive HER2-Negative Breast Cancer

    Serena 4: A Randomized, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

    Trial Details

About Amy M Schell

Featured HealthTalks